CompletedNCT03605849
Long-Term Safety of Centanafadine in Adults With ADHD
About this title
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Read the official source — NCT03605849Researchers studied Centanafadine SR, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
Researchers studied Centanafadine SR, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Culver CitySee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 14, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 662
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03605849
- Official title
Show the full official title
An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Get this study by email
Recruitment & locations
CompletedCulver City
Questions about this study
What did researchers investigate?
Researchers studied Centanafadine SR, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Centanafadine SR.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
